CONCORD, ON, Dec. 12, 2016 /CNW/ - Celopharma Inc, in collaboration with the sponsor, Linepharma International Limited, would like to provide an official update of the Mifegymiso distribution date.
Effective late January 2017 Mifegymiso (RU-486 early termination pill) will become available for use by women throughout Canada.
Company President Paula Tenenbaum was quoted as saying "indeed, this is a significant day that promises to improve the lives of Canadian women. By providing a new healthcare option, this medication expands the choices available to women across the country who need early termination of their pregnancy".
Ms. Tenenbaum went on to say "we very much appreciate the wonderful work of Health Canada and CADTH and the fairness they have both demonstrated towards the success of our application".
Mifegymiso is a combination medication—Mifepristone and Misoprostol. When taken sequentially the drug mimics a miscarriage and expels a pregnancy in someone up to seven weeks pregnant. The drug is already available in over 50 countries and it's included in the World Health Organization's list of essential medicines.
The drug has been lauded as an alternative method of abortion for those living in remote areas where accessing a surgical abortion would mean travelling great distances. Even in urban settings, where abortions are more readily available, it gives anyone wishing to terminate a pregnancy the option to do so in the privacy of their own home
Celopharma Inc., is a privately held, Canadian owned pharmaceutical company specializing in the licensing, regulatory, marketing and distribution of niche pharmaceutical products with their primary focus on women's health. www.celopharma.com
SOURCE Celopharma Inc
For further information: Paula Tenenbaum, President, Celopharma Inc., firstname.lastname@example.org, www.celopharma.com